Prochant Partners with Longshore Capital — PE Bets on Home-Based Care RCM

Prochant, a Charlotte-based technology-enabled RCM partner serving HME, DME, infusion, and specialty pharmacy providers, has announced a strategic growth partnership with Longshore Capital Partners. No financial terms were disclosed. This is another PE firm making a focused bet on a corner of revenue cycle that most of the market ignores — and the timing is not accidental.

What Prochant Does

Prochant operates squarely in the home-based care segment — HME, DME, infusion therapy, and specialty pharmacy. That's a billing environment defined by CMN documentation requirements, HCPCS coding complexity, prior authorization backlogs, and payer-specific coverage policies that change constantly. It's not the same RCM playbook that works for hospital systems or physician groups.

The company's pitch is specialized expertise plus technology-enabled workflows and analytics. In a segment where the billing errors are expensive (DME claims denied for documentation deficiencies cost providers real money in write-offs), verticalized knowledge matters more than scale. That's where Prochant has built its position.

Who Is Longshore Capital Partners?

Longshore focuses on lower middle-market businesses in technology-enabled services — a descriptor that fits Prochant precisely. The announcement language emphasizes leadership continuity and cultural preservation, which is the standard framing for a platform acquisition where the founding team's domain expertise is the asset. Joey Graham, Prochant's CEO, is staying and leading the next phase.

The "strategic growth partnership" framing — rather than acquisition — is deliberate. It signals that the management team retained meaningful equity and that Longshore is positioning as a capital and operational partner rather than an acquirer that will integrate Prochant into something else. That's a better structure for a business where client relationships and billing staff expertise are the primary competitive moat.

What the Investment Is Meant to Do

Per the announcement, Longshore's capital will fund:

• Technology and AI advancement — analytics, automation, and workflow tooling for home-based care billing
• Operational scale — more capacity to handle volume growth without proportional headcount increases
• Service expansion — likely adjacent specialties within the home-based care continuum
• Talent — recruiting and retaining billers and coders who know HME/DME cold
• Complementary acquisitions — tuck-ins within their core markets

The AI and automation line is the one to watch. Every PE-backed RCM services company is being pushed to demonstrate a credible automation story right now. For Prochant, that likely means AI-assisted prior auth tracking, automated CMN documentation validation, and denial reason code analytics that reduce write-off rates. The firms that build those capabilities into their workflow are going to command meaningfully better retention and margins.

What This Means for the Market

A few things worth noting for revenue cycle professionals tracking M&A in this space:

• Home-based care RCM is consolidating, just on a different timeline than physician/hospital RCM. The Ensemble/Optum/R1 wave swept through health system billing. The same consolidation is now playing out in HME and DME, where the market is more fragmented and the specialist operators have real moats.
• No disclosed amount means this is platform-stage capital. Longshore is building, not buying a mature asset. Expect follow-on acquisitions within 18–36 months as they look to add geographic coverage or specialty depth.
• The specialty pharmacy billing angle is strategically significant. Specialty pharmacy revenue cycle is one of the highest-complexity segments in healthcare billing — prior auth intensity, limited distribution channels, payer-specific formulary rules. Providers who handle specialty pharmacy billing well command premium pricing. Prochant's presence there is not incidental.
• Leadership continuity is the explicit promise. Graham stays, the team stays, culture stays. That matters because HME/DME billing relationships are long-term — clients don't want to re-train a new vendor team on their payor mix and exception patterns every two years.

If You're an HME or DME Provider

This deal doesn't change your billing operations tomorrow. But if Prochant is your vendor, or if you're evaluating them, a few questions are worth asking directly:

• What's the technology investment roadmap over the next 12 months — specifically around prior auth automation and denial analytics?
• Are there any planned service or pricing changes tied to the Longshore partnership?
• What does the acquisition pipeline look like — is Prochant pursuing tuck-ins that could affect staffing or operations?

PE-backed vendors under growth mandates make different decisions than founder-run businesses operating for long-term client retention. The good news here is that Longshore's emphasis on leadership continuity and the "partnership" framing suggests they understand the client relationship risk. But verify.

The Bottom Line

Prochant-Longshore is a well-structured bet on a segment of healthcare RCM that has real secular tailwinds and has historically been underinvested. The management team stays, the capital accelerates technology and scale, and Longshore gets a platform in a market with defensible specialization. That's the private equity playbook working as designed.

Watch for the AI automation announcement within the next 12 months. That's where the investment thesis gets validated or doesn't.

Source: PR Newswire, July 27, 2026